EML4-ALK fusion variant.3 and co-occurrent PIK3CA E542K mutation exhibiting primary resistance to three generations of ALK inhibitors

Kwak, 2010, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer, N Engl J Med, 363, 1693, 10.1056/NEJMoa1006448 Planchard, 2018, Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 29, iv192, 10.1093/annonc/mdy275 Lin, 2017, Targeting ALK: precision medicine takes on drug resistance, Cancer Discov, 7, 137, 10.1158/2159-8290.CD-16-1123 Mok, 2020, Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study, Ann Oncol, 10.1016/j.annonc.2020.04.478 Lin, 2018, Impact of EML4-ALK variant on resistance mechanisms and clinical outcomes in ALK-positive lung cancer, J Clin Oncol, 36, 1199, 10.1200/JCO.2017.76.2294 Tao, 2020, Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer, Lung Cancer, 149, 154, 10.1016/j.lungcan.2020.09.012 Blakely, 2017, Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers, Nat Genet, 49, 1693, 10.1038/ng.3990 Wang, 2015, EML4-ALK fusion detected by RT-PCR confers similar response to crizotinib as detected by fish in patients with advanced non-small-cell lung cancer, J Thorac Oncol, 10, 1546, 10.1097/JTO.0000000000000668 Roy, 2010, I-TASSER: a unified platform for automated protein structure and function prediction, Nat Protoc, 5, 725, 10.1038/nprot.2010.5 Waterhouse, 2018, SWISS-MODEL: homology modelling of protein structures and complexes, Nucleic Acids Res, 46, W296, 10.1093/nar/gky427 Humphrey, 1996, VMD: visual molecular dynamics, J Mol Graph, 14, 33, 10.1016/0263-7855(96)00018-5 Goto, 2016, Analysis of tumor-derived DNA in plasma and bone marrow fluid in lung cancer patients, Med Oncol, 33, 29, 10.1007/s12032-016-0744-x 2014, Cancer Genome atlas research N. comprehensive molecular profiling of lung adenocarcinoma, Nature, 511, 543, 10.1038/nature13385 Chakravarty, 2017, OncoKB: a precision oncology knowledge base, JCO Precis Oncol, 2017 Gao, 2013, Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Sci Signal, 6, pl1, 10.1126/scisignal.2004088 Conklin, 2013, Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent, J Thorac Oncol, 8, 45, 10.1097/JTO.0b013e318274a83e Gainor, 2016, Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer, Cancer Discov, 6, 1118, 10.1158/2159-8290.CD-16-0596 Katayama, 2012, Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers, Sci Transl Med, 4, 120ra17, 10.1126/scitranslmed.3003316 Doebele, 2012, Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer, Clin Cancer Res, 18, 1472, 10.1158/1078-0432.CCR-11-2906 Katayama, 2016, P-glycoprotein mediates ceritinib resistance in anaplastic lymphoma kinase-rearranged non-small cell lung cancer, EBioMedicine, 3, 54, 10.1016/j.ebiom.2015.12.009 Fukuda, 2019, Epithelial-to-mesenchymal transition is a mechanism of ALK inhibitor resistance in lung cancer independent of ALK mutation status, Cancer Res, 79, 1658, 10.1158/0008-5472.CAN-18-2052 Addeo, 2018, Precision medicine in ALK rearranged NSCLC: a rapidly evolving scenario, Crit Rev Oncol Hematol, 122, 150, 10.1016/j.critrevonc.2017.12.015 Mengoli, 2016, K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: report of two cases and review of the literature, Lung Cancer, 93, 55, 10.1016/j.lungcan.2016.01.002 Chaft, 2012, Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling, Mol Cancer Ther, 11, 485, 10.1158/1535-7163.MCT-11-0692 Zhao, 2005, The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells, Proc Natl Acad Sci USA, 102, 18443, 10.1073/pnas.0508988102 Isakoff, 2005, Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells, Cancer Res, 65, 10992, 10.1158/0008-5472.CAN-05-2612 Thorpe, 2015, PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting, Nat Rev Cancer, 15, 7, 10.1038/nrc3860 Han, 2014, Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma, Lung Cancer, 85, 161, 10.1016/j.lungcan.2014.04.009 Bray, 2019, Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients, Sci Rep, 9, 15365, 10.1038/s41598-019-51981-5 Tamura, 1992, Cardiac metastasis of lung cancer. a study of metastatic pathways and clinical manifestations, Cancer, 70, 437, 10.1002/1097-0142(19920715)70:2<437::AID-CNCR2820700211>3.0.CO;2-L Ardeshir-Larijani, 2018, KMT2D mutation is associated with poor prognosis in non-small-cell lung cancer, Clin Lung Cancer, 19, e489, 10.1016/j.cllc.2018.03.005